The ONE-MIND Study: Evaluating the Efficacy of Online Mindfulness-Based Cancer Recovery During Chemotherapy Treatment

Overview

Background: Chemotherapy treatment (CT) can have burdensome side effects such as fatigue, nausea-vomiting, and sleep problems that can significantly affect patients' quality of life. Fatigue is the most common, lasting and bothersome of these, which prevents people from working and carrying out daily activities. Mindfulness-Based Cancer Recovery (MBCR) is an evidence-based group training program which has shown to help treat negative physical and psychosocial symptoms in cancer patients. The investigators propose to evaluate a pilot-tested online-MBCR program for patients undergoing CT who may be low on energy, time or have compromised immunity. Objectives: To evaluate the impact of participation in online MBCR during CT on fatigue (primary outcome), sleep, pain, nausea/vomiting, mood disturbance, stress symptoms and quality of life (secondary outcomes) as well as cognitive function and return to work (exploratory outcomes) over the course of treatment. Methods: The study design is a randomized wait-list controlled trial, conducted during CT for patients with breast or colorectal cancer. Participants will take the 12-week online MBCR program at home within 2 weeks of randomization (immediate group) or after CT completion (waitlist group). Outcomes will be assessed online at, 1) Baseline, 2) Post-MBCR, 3) Post-CT (primary outcome) and 4) 12 months post-baseline. Anticipated Findings: MBCR is a promising adjuvant program that could help patients prevent, delay or diminish aversive symptoms and side-effects associated with CT, particularly fatigue. If helpful, online-MBCR could be made easily available at cancer centers worldwide and significantly lessen the burden of cancer treatments.

Full Title of Study: “The ONE-MIND Study: Evaluating the Efficacy of Online Mindfulness-Based Cancer Recovery (MBCR) During Chemotherapy Treatment (CT) to Impact Fatigue, Side Effects and Quality of Life (QL) in a Randomized Waitlist Controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Supportive Care
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: December 31, 2024

Interventions

  • Behavioral: Online Mindfulness Based Cancer Recovery (MBCR)
    • MBCR is a group behavioral treatment that trains participants in mindfulness techniques through meditation and gentle mindful movement

Arms, Groups and Cohorts

  • Experimental: Immediate MBCR group
    • The Online Mindfulness Based Cancer Recovery (MBCR) program intervention is delivered in 12 weekly real-time interactive 55-minute sessions offered over consecutive weeks.
  • Other: Waitlist control group
    • Treatment as usual, followed by a delayed (wait-list) intervention of the same Online Mindfulness Based Cancer Recovery (MBCR) program after the post-CT assessment.

Clinical Trial Outcome Measures

Primary Measures

  • Fatigue
    • Time Frame: 6 months
    • Fatigue will be measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F 68) is the most commonly-used cancer-related fatigue scale. Using a 5-point Likert scale (from “not at all” to “very much”), the 13-items reflect participants’ specific fatigue concerns in the past 7 days. The total score has well-established norms both in the literature and from our prior work and shows responsiveness to intervention

Participating in This Clinical Trial

Inclusion Criteria

1. Men and women over the age of 18 2. Diagnosed with either a) stage I-III HER 2 normal breast carcinoma or b) Stage II-III colorectal carcinoma 3. Scheduled to undergo either neoadjuvant or adjuvant: a) FEC- D or AC-T chemotherapy or b) FOLFOX or CAPEOX chemotherapy 4. Weekly access to high-speed internet 5. Access to a computer/tablet/smart phone 6. Able to attend MBCR classes at scheduled times 7. Sufficient ability to speak and read English 8. Willingness to be randomized into immediate or waitlist groups and complete all assessments Exclusion Criteria:

1. Metastatic patients 2. Suffering from current Major Depressive Disorder, Bipolar Disorder or other psychiatric disorder (self-report) 3. Currently engaging in meditation one or more times per week within the previous year. 4. Participation in an MBCR or MBSR program in the last five years. 5. Cognitive impairment (>6 on the Brief Screen for Cognitive Impairment) 6. Physical functional impairment that would interfere with the ability to participate in the intervention (on the PAR-Q questionnaire)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Calgary
  • Provider of Information About this Clinical Study
    • Principal Investigator: Linda E. Carlson, Enbridge Research Chair in Psychosocial Oncology – University of Calgary
  • Overall Official(s)
    • Linda E Carlson, PhD, Principal Investigator, University of Calgary
    • Barry D Bultz, PhD, Study Chair, University of Calgary
  • Overall Contact(s)
    • Linda E Carlson, PhD, 14033553207, lcarlso@ucalgary.ca

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.